Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01951638 · ClinicalTrials.gov registry record · Phase 2
Phase IIb Safety and Efficacy Study of Four Dose Regimens of BAY1021189 in Patients With Heart Failure and Preserved Ejection Fraction Suffering From Worsening Chronic Heart Failure (SOCRATES-PRESERVED)
A Phase 2 study, sponsored by Bayer.
- Completed
- Registry status
- Phase 2
- Development phase
- 477
- Enrollment target
NCT01951638 is a Phase 2 study that has completed, run by Bayer. The registered enrollment target is 477 participants.
The verdict
NCT01951638, a Phase 2 study, has completed, sponsored by Bayer.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 477 participants
- Enrollment target
Study Summary
Objective of the study is to find the optimal dose of the once daily oral soluble guanylate cyclase stimulator (sGC) BAY1021189 for Phase III that can be given in addition to standard diuretic and comorbidity treatment for heart failure with preserved ejection fraction (HFpEF)
Interventions
- DRUG Placebo
- DRUG Vericiguat (BAY1021189) (1.25 mg)
- DRUG Vericiguat (BAY1021189) (5 mg)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 477 participants |
| Start Date | 2013-11-06 |
| Est. Completion | 2015-09-16 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01951638
The ClinicalTrials.gov registry entry for NCT01951638 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 477 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bayer, which has 591 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT01951638 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01951638 about?
NCT01951638 is a clinical study titled "Phase IIb Safety and Efficacy Study of Four Dose Regimens of BAY1021189 in Patients With Heart Failure and Preserved Ejection Fraction Suffering From Worsening Chronic Heart Failure (SOCRATES-PRESERVED)". Objective of the study is to find the optimal dose of the once daily oral soluble guanylate cyclase stimulator (sGC) BAY1021189 for Phase III that can be given in addition to standard diuretic and comorbidity treatment for heart failure with preserved ejection fraction (HFpEF)
What is the current status of trial NCT01951638?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 477 participants. The study started on 2013-11-06. Estimated completion is 2015-09-16.
What interventions are being tested in trial NCT01951638?
The interventions under investigation include: Placebo (DRUG), Vericiguat (BAY1021189) (1.25 mg) (DRUG), Vericiguat (BAY1021189) (5 mg) (DRUG).
Who is sponsoring clinical trial NCT01951638?
This trial is sponsored by Bayer, which has 591 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.